CN101549057A - Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same - Google Patents

Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same Download PDF

Info

Publication number
CN101549057A
CN101549057A CNA2009100393813A CN200910039381A CN101549057A CN 101549057 A CN101549057 A CN 101549057A CN A2009100393813 A CNA2009100393813 A CN A2009100393813A CN 200910039381 A CN200910039381 A CN 200910039381A CN 101549057 A CN101549057 A CN 101549057A
Authority
CN
China
Prior art keywords
radix
condensed
fine powder
filters
vacuum drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CNA2009100393813A
Other languages
Chinese (zh)
Inventor
李志勇
张惜强
赖怀恩
苏和明
郑少鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGDONG HONGXING GROUP CO Ltd HONGXING PHARMACEUTICAL FACTORY
Original Assignee
GUANGDONG HONGXING GROUP CO Ltd HONGXING PHARMACEUTICAL FACTORY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGDONG HONGXING GROUP CO Ltd HONGXING PHARMACEUTICAL FACTORY filed Critical GUANGDONG HONGXING GROUP CO Ltd HONGXING PHARMACEUTICAL FACTORY
Priority to CNA2009100393813A priority Critical patent/CN101549057A/en
Publication of CN101549057A publication Critical patent/CN101549057A/en
Withdrawn legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a chinese medicinal composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same. The chinese medicinal composition is composed of components as follows: ginseng 150-800 weight parts, prepared fleece-flower root 2300-9200weight parts, safflower 650-2600weight parts, hawkthorn 1350-5400 weight parts, epimedium 1350-5400 weight parts, ginseng leaves 1000-4000 weight parts, grassleaved sweetflag 650-2600 weight parts, notoginseng 330-1320 weight parts, chuanxiong rhizome 750-3000 weight parts, salvia root 2000-8000 weight parts, mistletoe 1350-5400 weight parts, root of kudzu vine 1800-7200 weight parts, buffalo horn 4000-16000 weight parts, borneol 10-40 weight parts. Composition of the present invention is to supplement qi and activate blood circulation, disperse blood stasis and dredge collateral, regain consciousness, tranquilization and intelligence development, auxiliary nourishing the liver and kidney, regulating the spleen and stomach; complementing without dryness, running without losing, soft and moist with profit, without harm of cool, warm and dry, approaching objective of curing both deficiency and excess.

Description

A kind of Chinese medicine composition that is used for the treatment of hyperlipemia, cerebral arteriosclerosis and cerebral infarction and preparation method thereof
Technical field
The present invention relates to a kind of Chinese medicine composition, specifically a kind of Chinese medicine composition that is used for the treatment of cardiovascular and cerebrovascular diseases such as hyperlipemia, cerebral arteriosclerosis and cerebral infarction and preparation method thereof.
Background technology
Hyperlipemia, cerebral arteriosclerosis and cerebral infarction are the serial diseases of cardiovascular and cerebrovascular vessel, the Chinese and Western patent medicine that a lot of treatment cardiovascular and cerebrovascular diseases are arranged in the market, but it is how undesirable, though certain therapeutical effect is arranged mostly, but the toxic and side effects that has is bigger, the treatment cost that has is too high, and the back state of an illness of discontinuing medication occurs repeatedly, and Chinese medicine preparation safe, effective, of fine quality, easy to use still is clinical required.
Summary of the invention
The object of the present invention is to provide and a kind ofly can effectively treat Chinese medicine composition of cardiovascular and cerebrovascular diseases such as hyperlipemia, cerebral arteriosclerosis and cerebral infarction and preparation method thereof.
Treatment hyperlipemia of the present invention, the Chinese medicine composition of cerebral arteriosclerosis and cerebral infarction, make by following component: Radix Ginseng 150-600 weight portion, Radix Polygoni Multiflori Preparata 2300-9200 weight portion, Flos Carthami 650-2600 weight portion, Fructus Crataegi 1350-5400 weight portion, Herba Epimedii 1350-5400 weight portion, Folium Ginseng 1000-4000 weight portion, Rhizoma Acori Graminei 650-2600 weight portion, Radix Notoginseng 330-1320 weight portion, Rhizoma Chuanxiong 750-3000 weight portion, Radix Salviae Miltiorrhizae 2000-8000 weight portion, Herba Taxilli 1350-5400 weight portion, Radix Puerariae 1800-7200 weight portion, Cornu Bubali 4000-16000 weight portion, Borneolum Syntheticum 10-40 weight portion.
The Chinese medicine composition of treatment hyperlipemia of the present invention, cerebral arteriosclerosis and cerebral infarction can be made the dosage form on any pharmaceutics, comprises capsule, powder, granule, pill or tablet.
The preparation method of the various common formulations of Chinese medicine composition of the present invention is described respectively below:
1, the preparation of capsule: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, and mixing is granulated, and drying adds Borneolum Syntheticum fine powder and appropriate amount of auxiliary materials again, and mixing incapsulates, and promptly gets capsule.
2, the preparation of powder: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, mixing, and drying adds the Borneolum Syntheticum fine powder again, and mixing promptly gets powder.
3, the preparation of pill: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum fine powder, and with the general ball of ethanol, Radix Glycyrrhizae charcoal coating promptly gets pill.
4, the preparation of tablet: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, and mixing is granulated, and drying adds Borneolum Syntheticum fine powder and appropriate amount of auxiliary materials again, and mixing is pressed into tablet.
5, the preparation of granule: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum fine powder and appropriate amount of auxiliary materials, and mixing is granulated, and cold drying promptly gets granule.
Above-mentioned adjuvant is a magnesium stearate.
" deficiency of vital energy merger " opinion that we propose the apoplexy pathogenesis according to the famous medical scholar's Wang Qingren of the Qing Dynasty, in conjunction with modern times pharmacology, pharmacy to aspect researchs such as blood fat reducing, microcirculation improvement, treatment cerebral infarction the efficacious prescriptions medicine arranged, carry out comprehensive, analyze, determined Chinese medicine composition of the present invention and preparation method thereof after relatively.Radix Ginseng strongly invigorating primordial QI in the prescription of the present invention, QI invigorating power wins especially; Pseudo-ginseng blood-circulation-invigovating is promoted blood circulation, promoting tissue regeneration by removing blood stasis; The Radix Polygoni Multiflori Preparata invigorating the liver and kidney, beneficial marrow is supplemented nutrition in brain, is monarch drug.Be aided with Rhizoma Chuanxiong, Flos Carthami, Radix Salviae Miltiorrhizae, Fructus Crataegi promoting flow of QI and blood, blood stasis dispelling eliminate indigestion, activating collaterals and eliminating stagnation; Herba Taxilli, Herba Epimedii invigorating the liver and kidney, the resistance of benefiting essence-blood blood stasis dispelling are ministerial drug.Assistant is diathermanous with the Radix Puerariae expelling pathogenic factors from muscles, the yang invigorating collateral dredging; The Cornu Bubali clearing away heat and cooling blood, detoxifcation dissipating rashes, the stagnant strongly fragrant heat of changing of a specified duration of the clear stasis of blood altogether; The Folium Ginseng nourishing YIN to relieve dryness, the Fructus Alpiniae Oxyphyllae of calming the nerves is adjuvant drug; The Borneolum Syntheticum stagnated fire of loosing, logical all keys; Rhizoma Acori Graminei causing resuscitation with aromatic drugs, brain healthy are for making, and all medicines share plays benefiting QI for activating blood circulation altogether, disperse blood stasis and dredge collateral, consciousness-restoring and orifice-opening, nourishing the liver and kidney, the effect of the Fructus Alpiniae Oxyphyllae of calming the nerves.
Below, the drug action of Chinese medicine composition of the present invention is described by zoopery:
In order to inquire into the therapeutic effect of medicine of the present invention to cardiovascular and cerebrovascular disease; combination of Chinese and Western medicine institute carries out pharmacodynamic study through Chinese PLA No.1 Military Medical Univ., has observed blood fat, blood viscosity microcirculation, rat cerebral ischemia are organized the influence of lipid peroxide content and the Ultrastructural protective effect of rat ischemia sexually transmitted disease (STD) mould cerebral tissue etc.
(1), to the influence of blood fat
Medicine of the present invention is given hyperlipidemia model rat 2.1g/kg and two groups of 4.2g/kg and matched group relatively, all there were significant differences for total cholesterol level, content of triglyceride (P<0.05,0.01), and significant dose-effect relationship is arranged, relatively there is not significant difference (P>0.05) with clofibrate.
The content of high density lipoprotein, medicine group of the present invention and high fat matched group relatively have the raising (P<0.01) of highly significant, and the clofibrate group is not seen this effect.
Dissect finding, give high lipid food for a long time, each group sees that all fatty liver forms, and high fat matched group accounts for 92.8%, and the clofibrate group accounts for 77.8%, and medicine of the present invention is 61.5%, 61.1% for two groups, through X 2Handle, there were significant differences for matched group and administration group (P<0.05).
(2), to the influence of blood circulation
1, the intravenous injection of medicine of the present invention (N=8) 10mg/100g dosage can make the rat brain blood flow increase, increase by 57.1 ± 18.17% in the time of 20 minutes, can keep 40-50 minute, with comparison before the administration, highly significant difference (P<0.01) is arranged, relatively act on slow slightly with the 0.5ml/100g sodium nitrite.
2, medicine of the present invention (N=8) 2.5mg/100g makes cardiac perfusion, can make the coronary flow of isolated heart increase by 38.9%, with comparison before the administration, highly significant difference (P<0.01) is arranged.1% sodium nitrite perfusion, coronary flow increases by 25%, and not as good as medicine of the present invention, both comparing differences are (P<0.05) significantly.
3, to rat small intestine injection 0.4ml/100g body weight medicine of the present invention, arteriole pipe, thin vein pipe all significantly enlarge after five minutes, compare with matched group, difference highly significant (P<0.01), the open number of capillary tube increases by 41.9 ± 14.1% for every square millimeter, the capillary tube bore increases, with matched group comparing difference remarkable (P<0.05).Duration of efficacy 30~40 minutes, blood flow rate are generally than improving one-level before the administration.
(3), to the influence of cerebrum ischemia sexually transmitted disease (STD) mould
1, medicine 0.2mg/100g of the present invention and 0.4g/100g are two groups, nifedipine positive controls 2.5mg/100g and normal control group, after the administration three days, the ligation bilateral carotid, broken end is got brain after 15 hours, measures LPO content, and each administration group LPO is starkly lower than matched group, high dose group LPO content is minimum, with low dose group and nifedipine group notable difference (P<0.05) is arranged more all.
2, above-mentioned model is got cerebral tissue, fixes with glutaraldehyde, and dehydrated slice is used JEM120EX electron microscopic observation neuronal cell, oligodendroglia and the Ultrastructural variation of capillary tube routinely.From the observed result analysis, medicine of the present invention all has protective effect to neuronal cell, oligodendroglia and the capillary tube ultrastructure of rat ischemia sexually transmitted disease (STD) mould, and its effect is better than nifedipine slightly.
(4), to the influence of blood viscosity
Healthy SD rat 4.5g/kg/d gastric infusion is measured whole blood viscosity and plasma viscosity, and compares (37.5S under low tangent condition with normal control group, acenocoumarol matched group -1) medicine group of the present invention is starkly lower than matched group (P<0.05), with acenocoumarol group no significant difference (P>0.05).
(5), to the influence of mice swimming endurance
Medicine group of the present invention and matched group relatively have highly significant difference (P<0.05), show that medicine of the present invention has the effect that improves mice endurance.
Pharmacodynamic experiment shows that medicine of the present invention has the effect of cerebral blood flow increasing amount, coronary flow and microcirculation improvement; The free radical that obviously suppresses the cerebral ischemia tissue forms, and the cerebral ischemia tissue is had protective effect, can alleviate the cerebral tissue neurocyte necrosis that is caused by the cerebral tissue ischemia.To circulation disorder, because the content of anticoagulant, blood viscosity lowering, blood fat reducing, raising high density lipoprotein, so certain preventive effect is arranged.Therefore, control coronary artery, cerebrovascular sclerosis and thromboembolism there is positive effect.
Below, the therapeutic effect and the safety of medicine of the present invention are described by the clinical drug development test:
Medicine of the present invention carries out clinical trial at the attached SHUGUANG HOSPITAL of Shanghai College of Traditional Chinese Medicine, Longhua hospital, Yueyang hospital, Ruijin Hospital Attached to Shanghai Medical Univ No.2.Treatment cerebral arteriosclerosis, cerebral infarction and apoplexy sequela, hyperlipemia be totally 377 examples (male 215 examples, women 162 examples, 63 ± 10 years old age, minimum 40 years old, maximum 80 years old).Dosage is each 2-4 grain, and every day three times, one month is a course of treatment.Treat 1-4 the course of treatment, total obvious effective rate is 50.13%, and total effective rate is 89.92%, wherein: treatment cerebral arteriosclerosis 130 examples, obvious effective rate 50.00%, effective percentage 88.46%; Treatment cerebral infarction and apoplexy sequela 169 examples, obvious effective rate 40.24%, effective percentage 93.49%, CT head simple scan is checked 111 examples before the Ischemic Apoplexy Patients treatment, wherein 45 example treatments are after CT obvious effective rate 15.6%, CT effective percentage 57.8% are checked in the scanning of CT head; Treatment hyperlipemia 78 examples, obvious effective rate 71.79%, effective percentage 74.61%.And compare with nitric acid removing obstruction from collaterals pill 50 examples, both curative effects of treatment cerebral arteriosclerosis are similar; Treatment cerebral infarction and apoplexy sequela, medicine group curative effect of the present invention is better than matched group, through X 2Analyze P<0.01.To symptom total effective rates such as patient headache, dizzy, numb limbs and tense tendons is 90.93%, and wherein the dizzy curative effect of primary symptom is better than matched group, analyze through Ridit, and P<0.05, other symptom effective percentage are higher than matched group mostly.To the various recovery from dysfunction obvious effective rates 56.87% of stroke patient, effective percentage 87.12%.Medicine of the present invention has better reduction serum cholesterol, serum triglycerides, atherogenic index, the effect of rising lipid carrier HDL-C detects 296 examples before and after the treatment altogether, checks through own control t, there is the meaning of highly significant P value<0.001.Medicine of the present invention all has significant improvement effect to hemorheological indexes, detect 288, projects such as whole blood viscosity (height is cut, hanged down and cut), plasma viscosity, Fibrinogen, own control t checks, the P value all<0.001, difference has the highly significant meaning before and after the treatment; Reduce the platelet aggregation index, P<0.05, significance.Medicine of the present invention has no adverse effects to hemogram, liver function, renal function.Diseases such as Drug therapy cerebral arteriosclerosis of the present invention, cerebral infarction and apoplexy sequela, hyperlipemia have significant effect.
Medicine of the present invention is used for the apoplexy cerebral infarction and sees that the blood stasis due to qi deficiency patient is arranged, and can obviously improve symptom and motion, aphasis, and aspect tools such as hemorheological property are had some improvement.Total effective rate is 90.91%, and obvious effective rate is 40%, compares with matched group XIAOSHUAN TONGLUO PIAN group, and credit is analysed by statistics, and highly significant difference (P<0.001) is arranged between two groups, shows that medicine group of the present invention is better than the XIAOSHUAN TONGLUO PIAN group; CT total effective rate 58.18% compares with matched group XIAOSHUAN TONGLUO PIAN group, and two groups there were significant differences (P<0.05), shows that medicine group of the present invention is better than the XIAOSHUAN TONGLUO PIAN group; To symptom normalization rate such as not smoothgoing puckery, the headache of hemiplegia, speech, tired, numb limbs and tense tendons and matched group XIAOSHUAN TONGLUO PIAN group relatively, through X 2Analyze, P<0.05 shows that medicine group of the present invention is better than the XIAOSHUAN TONGLUO PIAN group.Other symptom normalization rates and XIAOSHUAN TONGLUO PIAN group compare, and curative effect is similar.
The specific embodiment
The present invention will be described in detail by the following examples, but they are not limitation of the invention.
Embodiment 1: the preparation of capsule
Take by weighing raw material by following consumption: Radix Ginseng 300 weight portions, Radix Polygoni Multiflori Preparata 4600 weight portions, Flos Carthami 1300 weight portions, Fructus Crataegi 2700 weight portions, Herba Epimedii 2700 weight portions, Folium Ginseng 2000 weight portions, Rhizoma Acori Graminei 1300 weight portions, Radix Notoginseng 660 weight portions, Rhizoma Chuanxiong 1500 weight portions, Radix Salviae Miltiorrhizae 3000 weight portions, Herba Taxilli 2700 weight portions, Radix Puerariae 3600 weight portions, Cornu Bubali 8000 weight portions, Borneolum Syntheticum 20 weight portions.
Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 23 times, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, and mixing is granulated, and drying adds Borneolum Syntheticum fine powder and magnesium stearate again, and mixing incapsulates, and promptly gets capsule.
Embodiment 2: the preparation of powder
Take by weighing raw material by following consumption: Radix Ginseng 200 weight portions, Radix Polygoni Multiflori Preparata 4000 weight portions, Flos Carthami 1300 weight portions, Fructus Crataegi 1500 weight portions, Herba Epimedii 2500 weight portions, Folium Ginseng 2000 weight portions, Rhizoma Acori Graminei 1300 weight portions, Radix Notoginseng 650 weight portions, Rhizoma Chuanxiong 1200 weight portions, Radix Salviae Miltiorrhizae 3500 weight portions, Herba Taxilli 2600 weight portions, Radix Puerariae 3750 weight portions, Cornu Bubali 7500 weight portions, Borneolum Syntheticum 25 weight portions.
Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 3 times, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, mixing, and drying adds the Borneolum Syntheticum fine powder again, and mixing promptly gets powder.
Embodiment 3: the preparation of pill
Take by weighing raw material by following consumption: Radix Ginseng 300 weight portions, Radix Polygoni Multiflori Preparata 4000 weight portions, Flos Carthami 1200 weight portions, Fructus Crataegi 2400 weight portions, Herba Epimedii 2400 weight portions, Folium Ginseng 2500 weight portions, Rhizoma Acori Graminei 1200 weight portions, Radix Notoginseng 800 weight portions, Rhizoma Chuanxiong 2000 weight portions, Radix Salviae Miltiorrhizae 3000 weight portions, Herba Taxilli 2500 weight portions, Radix Puerariae 4000 weight portions, Cornu Bubali 7500 weight portions, Borneolum Syntheticum 20 weight portions.
Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 3 times, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum fine powder, and with the general ball of ethanol, Radix Glycyrrhizae charcoal coating promptly gets pill.
Embodiment 4: the preparation of tablet
Take by weighing raw material by following consumption: Radix Ginseng 400 weight portions, Radix Polygoni Multiflori Preparata 4200 weight portions, Flos Carthami 1300 weight portions, Fructus Crataegi 2500 weight portions, Herba Epimedii 2500 weight portions, Folium Ginseng 2000 weight portions, Rhizoma Acori Graminei 2000 weight portions, Radix Notoginseng 750 weight portions, Rhizoma Chuanxiong 1500 weight portions, Radix Salviae Miltiorrhizae 3000 weight portions, Herba Taxilli 3200 weight portions, Radix Puerariae 3500 weight portions, Cornu Bubali 7000 weight portions, Borneolum Syntheticum 25 weight portions.
Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, and mixing is granulated, and drying adds Borneolum Syntheticum fine powder and magnesium stearate again, and mixing is pressed into tablet.
Embodiment 5: the preparation of granule
Take by weighing raw material by following consumption: Radix Ginseng 400 weight portions, Radix Polygoni Multiflori Preparata 4000 weight portions, Flos Carthami 1500 weight portions, Fructus Crataegi 2400 weight portions, Herba Epimedii 2800 weight portions, Folium Ginseng 3200 weight portions, Rhizoma Acori Graminei 1400 weight portions, Radix Notoginseng 650 weight portions, Rhizoma Chuanxiong 2500 weight portions, Radix Salviae Miltiorrhizae 3500 weight portions, Herba Taxilli 2800 weight portions, Radix Puerariae 2800 weight portions, Cornu Bubali 8000 weight portions, Borneolum Syntheticum 25 weight portions.
Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 3 times, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum fine powder and magnesium stearate, and mixing is granulated, and cold drying promptly gets granule.

Claims (8)

1, a kind of hyperlipemia that is used for the treatment of, the Chinese medicine composition of cerebral arteriosclerosis and cerebral infarction, it is characterized in that, make by following component: Radix Ginseng 150-600 weight portion, Radix Polygoni Multiflori Preparata 2300-9200 weight portion, Flos Carthami 650-2600 weight portion, Fructus Crataegi 1350-5400 weight portion, Herba Epimedii 1350-5400 weight portion, Folium Ginseng 1000-4000 weight portion, Rhizoma Acori Graminei 650-2600 weight portion, Radix Notoginseng 330-1320 weight portion, Rhizoma Chuanxiong 750-3000 weight portion, Radix Salviae Miltiorrhizae 2000-8000 weight portion, Herba Taxilli 1350-5400 weight portion, Radix Puerariae 1800-7200 weight portion, Cornu Bubali 4000-16000 weight portion, Borneolum Syntheticum 10-40 weight portion.
2, the described Chinese medicine composition of claim 1 is characterized in that it is capsule, powder, pill, tablet or granule.
3, the preparation method of the described Chinese medicine composition of claim 2 is characterized in that, comprises following production stage: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, and mixing is granulated, and drying adds Borneolum Syntheticum fine powder and appropriate amount of auxiliary materials again, and mixing incapsulates, and promptly gets capsule.
4, the preparation method of the described Chinese medicine composition of claim 2 is characterized in that, comprises following production stage: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, mixing, and drying adds the Borneolum Syntheticum fine powder again, and mixing promptly gets powder.
5, the preparation method of the described Chinese medicine composition of claim 2 is characterized in that, comprises following production stage: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum fine powder, and with the general ball of ethanol, Radix Glycyrrhizae charcoal coating promptly gets pill.
6, the preparation method of the described Chinese medicine composition of claim 2 is characterized in that, comprises following production stage: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng fine powder, and mixing is granulated, and drying adds Borneolum Syntheticum fine powder and appropriate amount of auxiliary materials again, and mixing is pressed into tablet.
7, the preparation method of the described Chinese medicine composition of claim 2 is characterized in that, comprises following production stage: Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum are ground into fine powder respectively; Cornu Bubali is rasped to filament, decocts with water 1-3 time, filters, and merging filtrate is condensed into thick paste, vacuum drying; Folium Ginseng decocts with water secondary, filters, and merging filtrate is condensed into clear paste, adds ethanol, stirs, and leaves standstill 24 hours, filters, and filtrate recycling ethanol is condensed into thick paste, vacuum drying; Nine flavors such as all the other Radix Polygoni Multiflori Preparatas, Flos Carthami, Fructus Crataegi, Herba Epimedii, Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Herba Taxilli, Radix Puerariae decoct with water three times, filter, and merging filtrate is condensed into thick paste, vacuum drying.Above dry extract is ground into fine powder, adds Radix Ginseng, Radix Notoginseng, Borneolum Syntheticum fine powder and appropriate amount of auxiliary materials, and mixing is granulated, and cold drying promptly gets granule.
8, the preparation method of any described Chinese medicine composition of claim 3~7 is characterized in that, described adjuvant is a magnesium stearate.
CNA2009100393813A 2009-05-10 2009-05-10 Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same Withdrawn CN101549057A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2009100393813A CN101549057A (en) 2009-05-10 2009-05-10 Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2009100393813A CN101549057A (en) 2009-05-10 2009-05-10 Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011101715703A Division CN102225132A (en) 2009-05-10 2009-05-10 Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof

Publications (1)

Publication Number Publication Date
CN101549057A true CN101549057A (en) 2009-10-07

Family

ID=41153700

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2009100393813A Withdrawn CN101549057A (en) 2009-05-10 2009-05-10 Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same

Country Status (1)

Country Link
CN (1) CN101549057A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103404650A (en) * 2013-08-19 2013-11-27 北京绿源求证科技发展有限责任公司 Heart-nourishing tea infusion
CN103845604A (en) * 2012-12-04 2014-06-11 天津市宝恒生物科技有限公司 Method for producing health-care product for reducing blood fat
CN104383190A (en) * 2013-11-28 2015-03-04 秦佑胜 Agent for treating qi deficiency and blood stasis type ischemic stroke

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103845604A (en) * 2012-12-04 2014-06-11 天津市宝恒生物科技有限公司 Method for producing health-care product for reducing blood fat
CN103404650A (en) * 2013-08-19 2013-11-27 北京绿源求证科技发展有限责任公司 Heart-nourishing tea infusion
CN104383190A (en) * 2013-11-28 2015-03-04 秦佑胜 Agent for treating qi deficiency and blood stasis type ischemic stroke

Similar Documents

Publication Publication Date Title
CN1148211C (en) Medicine for treating congestive heart failure
CN1051237C (en) Meicinal prepn. "Kexianling" for curing epilepsy
CN101708237B (en) Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof
CN1899598A (en) Combined medicine for preventing and treating rheumatism, rheumatoid, protrusion of intervertebral disc and hyperosteogeny
CN101095768B (en) Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age
CN102579610B (en) Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof
CN101843694A (en) Chinese medicament for treating chronic hepatitis
CN101549057A (en) Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same
CN105106758A (en) Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness
CN105250427A (en) Pharmaceutical composition for treating heart diseases
CN102836338B (en) Chinese medicament for treating cardia-cerebrovascular diseases
CN105311492A (en) Medicine for treating coronary atherosclerotic heart disease
CN1101199C (en) Chinese-medicinal capsule for treating hyperlipomia
CN102225132A (en) Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof
CN1286500C (en) Medication for treating numbness of the muscles and painful joints
CN1111054C (en) Medicine for treating apoplexy and its preparing process
CN1245197C (en) Chinese medicine preparation for treating coronary heart disease and viral myocarditis
CN101564505A (en) Chinese medicament for treating pulmonary heart disease
CN1136899C (en) Chinese medicine for treating mastoplasia
CN1319586C (en) Medicinal composition for treating brain apoplexy
CN114617939B (en) Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy
CN103356951B (en) A kind of Chinese medicine composition for the treatment of cardiac blood supply deficiency
CN110215474B (en) Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof
CN101850046B (en) Chinese medicament for treating chronic hepatitis
CN101530479B (en) Traditional Chinese medicine for treating diabetes mellitus and muscle atrophy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Li Zhiyong

Inventor after: Xie Jinshun

Inventor after: Zhang Xiqiang

Inventor after: Lai Huaien

Inventor after: Su Heming

Inventor after: Zheng Shaoxin

Inventor after: Yang Baoru

Inventor after: Lai Shurong

Inventor after: Wei Jian

Inventor after: He Jisheng

Inventor before: Li Zhiyong

Inventor before: Zhang Xiqiang

Inventor before: Lai Huaien

Inventor before: Su Heming

Inventor before: Zheng Shaoxin

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: LI ZHIYONG ZHANG XIQIANG LAI HUAIEN SU HEMING ZHENG SHAOXIN TO: LI ZHIYONGZHANG XIQIANG LAI HUAIEN SU HEMING ZHENG SHAOXIN YANG BAORU LAI SHURONG WEI JIAN HE JISHENG XIE JINSHUN

C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Open date: 20091007